

## The right TEVAR stent-graft, every time

---

# AllStent Accepted into the ECHO 2025 Experiential Training Program to compete for C\$250,000 prize

---

**ECHO -Entrepreneurship for Cardiovascular Health Opportunities, Canada, is training the next generation of innovators in all aspects of advancing cardiovascular care**

Planned Date of release: Monday 28<sup>th</sup> October

Locations: Toronto, Canada; and Milan, Italy

AllStent, with Business, Finance and Regulatory operations in Toronto, Canada; and Research & Development in Milan, Italy, is pleased to announce it has been accepted into the ECHO 2025 cohort in Toronto, Canada.

ECHO -Entrepreneurship for Cardiovascular Health Opportunities, is a Canadian national entrepreneurship training program designed to bridge the translational gap for cardiovascular innovations.

**Paul Chipperton, AllStent's CEO based in Toronto, Canada,** is a serial Medtech founder and entrepreneur (Nasdaq:prof) who annually lectures Masters course in Strategic Innovation, Entrepreneurship, Marketing and Venture Finance at University of Toronto's TRP and IMI Faculties, as well as Politecnico di Milano's Master of Biomedical Engineering.

*"From day-1 of discussions with the scientific founding team of AllStent we had the ambition to be global in scope and delivery. Hence it was a perfect fit to introduce our young, female, multi-lingual team of PhDs and post-Docs in Italy to the more rambunctious dynamics of the North America market and marketing experience, and ready the company for Health Canada, EU-MDR and US-FDA. ECHO's training and guidance is the definition of best fit at the right time."*

**Dr. Sara Barati PhD, AllStent Founding AI/ML Scientific Development Advisor enthused**

"I am thrilled to be accepted into the ECHO program, as it presents a unique opportunity to accelerate the impact of our innovations in cardiovascular health. This program will not only bridge critical gaps in translating our technology but also provide valuable mentorship and resources to bring our solutions closer to improving patient outcomes. At AllStent, we are dedicated to advancing AI/ML-driven solutions for complex cardiovascular challenges, and

with ECHO's support, we are confident that we can push the boundaries of what's possible in the field of cardiovascular care."

### **Dr Soror Sharifpoor, Co-founder of ECHO; and Director, Strategy & Translation at Ted Rogers Centre for Heart Research added**

"At the ECHO program, our mission is to accelerate the commercialization of life-changing cardiovascular innovations and their transfer from bench to bedside through a customized and comprehensive training program, strategic mentorship, smart partnership opportunities and financial support. This year we have admitted 13 promising ventures from across Canada to ECHO and we are thrilled to welcome AllStent and their exceptional founders to our 2024-2025 cohort. With their innovative and patient-centric TEVAR stent implantation modelling and surgical preplanning technology, AllStent is poised to improve the outcomes of complex cardiac interventions."

### **LINKS**

[www.allstent.com](http://www.allstent.com)

<https://www.polimi.it/>

<https://tedrogersresearch.ca/echo/>

<https://www.utm.utoronto.ca/imi/>

<https://trp.utoronto.ca/>

### **ABOUT AllStent**

AllStent was formed in July 2024 as a spin-out of Politecnico di Milano, Italy (PoliMi), co-founded by a young female team of PhD's and Post-Docs from Dr Migliavacca's *in silico* medicine group in Computational Biomechanics. Just since 2019, with >70 academic peer-reviewed publications on the topics of cardiovascular and neurovascular mechanics, the company was formed to commercialise in the area of greatest need, pre-operative planning and post-operative complication assessment of complex TEVAR surgeries.

Delivering an unmet market pull directly from surgeons, AllStent is offering unique patient-specific high-fidelity 3D-simulations and accurate "digital twins" of the anatomy and TEVAR procedure, range of optimal stent-grafts, best-fit and post-deployment risk analysis.

**ALLSTENT MEDIA CONTACT**



Paul Chipperton

E: [CEO@allstent.com](mailto:CEO@allstent.com)

T: +1 647 291 8545